Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer (Industry)

Overall Status

Completed

CT.gov ID

NCT00167960

Collaborator

(none)

1,500

Enrollment

Locations

750

Patients Per Site

Study Details

Study Description

Brief Summary

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Condition or Disease	Intervention/Treatment	Phase
Gram-Positive Bacterial Infections	Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase

Study Design

Study Type:

Observational

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.

Study Start Date :

Jan 1, 2005

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All patients admitted to or transferred to the SICU.
Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
Provide written informed consent

Exclusion Criteria:

Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
Females who are pregnant and breast feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
Those who have already been participating other clinical study related with antibiotics.